Table 1.
Clinical trials of favipiravir.
| Study name | Study design | Intervention type | Condition | Identifier (phase) | Population number |
|---|---|---|---|---|---|
| Favipiravir in COVID-19 | Open | Drug therapy | Intensive care, intubation, endotracheal, SARS-CoV-2 infection (COVID-19) | / | 7 |
| Favipiravir in COVID-19: the VIRCO and NCT04445467 studies | Placebo-controlled, randomized |
Drug therapy | SARS-CoV-2 infection (COVID-19) | NCT04445467 | 190 |
| Favipiravir in COVID-19: the NCT04346628 study | Open, randomized |
Drug therapy | SARS-CoV-2 infection (COVID-19) | NCT04346628 | 120 |
| Favipiravir in COVID-19: the NCT04351295 study | Open, placebo-controlled, randomized |
Drug therapy | SARS-CoV-2 infection (COVID-19) | NCT04351295 | 40 |
| Favipiravir in COVID-19: the NCT04333589 study | Open, randomized |
Drug therapy | SARS-CoV-2 infection (COVID-19) | NCT04333589 | 210 |
| Favipiravir in COVID-19/viral pneumonia: the NCT04336904 study | Double-blind, placebo-controlled, randomized |
Drug therapy | Pneumonia, viral, SARS-CoV-2 infection (COVID-19) |
NCT04336904 | 100 |
| Favipiravir in SARS-CoV-2 infection (COVID-19): the NCT04402203 study | Double-blind, placebo-controlled, randomized | Drug therapy | SARS-CoV-2 infection (COVID-19) | NCT04402203 | 50 |
| Favipiravir in COVID-19: the Avi-Mild and NCT04464408 studies | Double-blind, multicentre, placebo-controlled, randomized |
Drug therapy | SARS-CoV-2 infection (COVID-19) | NCT04464408 | 576 |
| Favipiravir in SARS-CoV-2 infection (COVID-19): the NCT04358549 study | Open, randomized |
Drug therapy | SARS-CoV-2 infection (COVID-19) | NCT04358549 | 50 |
| Favipiravir in COVID-19: the NCT04425460 study | Double-blind, placebo-controlled, randomized |
Drug therapy | SARS-CoV-2 infection (COVID-19) | NCT04425460 | 256 |
| Favipiravir in SARS-CoV-2 infection (COVID-19)/respiratory tract infection prevention: the NCT04448119 study CONTROL-COVID | Double-blind, placebo-controlled, randomized | Prevention | SARS-CoV-2 infection (COVID-19) | NCT04448119 | 760 |
| Favipiravir or lopinavir/ritonavir in SARS-CoV-2 infection (COVID-19) | Open | Drug therapy | SARS-CoV-2 infection (COVID-19) | / | 80 |
| Favipiravir vs. hydroxychloroquine in COVID-19: the NCT04387760 study | Comparative, open | Drug therapy | SARS-CoV-2 infection (COVID-19) | NCT04387760 | 150 |